

COMPANY

Stromedix is a clinical-stage biotechnology company developing novel drugs to treat fibrosis and fibrotic organ failure. Our lead program, STX-100, is in a Phase 1 clinical trial.

Stromedix is led by a team of seasoned biotechnology industry veterans with deep experience in drug development. The company has also created a strong network of medical and scientific advisers. The company will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer.

FIBROSIS AND CHRONIC ORGAN FAILURE

Fibrosis results from the body's attempt to repair chronic tissue injury. Ongoing cycles of injury and repair, often playing out over decades, lead to accumulation of scar tissue in affected organs and disruption of normal tissue architecture and function. In short, the organ fails. Fibrosis is a final common pathway in virtually all forms of chronic organ failure, whether in kidney, liver, lung, or elsewhere. Moreover, the biology of fibrosis is similar, regardless of cause – viral, chemical, physical or inflammatory. Fibrosis results from the excessive activity of fibroblasts, in particular a differentiated form known as the myofibroblast. The biology of these cells is well understood and scientists believe that drugs that attenuate myofibroblast activity ought to slow or perhaps even reverse the progression of fibrosis, restoring organ function and prolonging healthy life.

THERAPEUTIC PIPELINE

STX-100 is a humanized monoclonal antibody targeting integrin $\alpha v \beta 6$ licensed from Biogen Idec. STX-100 exhibits significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease. Stromedix is developing STX-100 initially for the treatment of chronic allograft dysfunction in kidney transplant recipients.

Stromedix believes that $\alpha v \beta 6$ blockade may have therapeutic utility in a broad array of chronic organ failure settings, acute organ failure and cancer.

MANAGEMENT

Michael Gilman, Ph.D.

Co-Founder and Chief Executive Officer

Neil Kirby, Ph.D.

Chief Development Officer

Brad Maroni, M.D.

Chief Medical Officer

Shelia Violette, Ph.D.

Vice President, Research

Daniel Lynch

Executive Chairman

INVESTORS

Stromedix has raised \$29.4 million in two rounds. Investors include Atlas Venture, Bessemer Venture Partners, Frazier Healthcare Ventures, New Leaf Venture Partners, and Red Abbey Venture Partners. Biogen Idec is also a shareholder.

CONTACT

For all business development inquiries, please contact:

Eric Huang, Ph.D.

*Associate Director, Corporate Development and Planning
eric.huang@stromedix.com*

**One Canal Park, Suite 1120
Cambridge, MA 02141
Tel: +1 (617) 674-8400
Fax: +1 (617) 674-8390
www.stromedix.com**